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Purpose/Background: Sarcopenia (decrease of muscle mass and function) has been linked with atherosclerosis [1]. The 
EWGSOP2 updated consensus, uses low muscle strength as the primary indicator of sarcopenia [2]. It is acknowledged that 
strength is better than mass for predicting adverse outcomes [2]. Handgrip strength (HGS) is a simple assessment to estimate 
overall muscular strength [3]. and is associated with cardiovascular mortality [4].
Objective: Analyze the relationship between HGS and atherosclerotic disease (carotid artery disease + lower extremity artery 
disease).
Methods: Prospective observation study was conducted from January to December 2019. The clinical and demographic data 
was recorded. Isometric HGS was measured with an adjustable handheld dynamometer (Jamar The higher value of each arm 
was used to classify the patient as sarcopenic or non-sarcopenic. Definition of sarcopenia: HGS <30 kgf in men and <20 kgf in 
women [5].
Results: 94 patients (aged 44–86 years) were analyzed: 64 sarcopenic and 30 non sarcopenic. Groups differed in the prevalence 
of diabetes and smoking status (Table 1). No differences were found in the carotid parameters analyzed (Table 1). There was, a 
difference in the prevalence of chronic limb-threatening ischemia (CLTI) in sarcopenic versus non-sarcopenic group (23.44% 
versus 6.67% p = 0.046). Importantly, binary logistic regression showed that diabetes (p = 0.014), and HGS (p = 0.027) have a 
significant effect on CLTI (Table 2).
Conclusions: No relationship was found between sarcopenia (measured by HGS) and carotid atherosclerosis, differing from 
other authors [1,6]. In this study, sarcopenic had a higher incident of diabetes and CLTI. Sarcopenia and diabetes are reciprocally 
related and may share a similar pathogenetic pathway [7,8,9].
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Table 1
Sarcopenia (n = 64) No Sarcopenia (n = 30) p
Age (years) 69.81 ± 8.79 62.6 ± 8.61 p = 0.889
Male 47 (73.44%) 27 (90.00%) p = 0.067
Hypertension 51 (79.69%) 21 (70.00%) p = 0.301
Dyslipidemia 47 (73.43%) 18 (60.00%) p = 0.189
Smoking load (UMA) 24.42 ± 33.14 37.76 ± 31.8 p = 0.748
Smoker/Ex-smoker 33 (51.56%) 24 (80.00%) p = 0.013*
Diabetes 28 (43.75%) 7 (23.33%) p = 0.049*
Coronary disease 11 (17.19%) 4 (13.33%) p = 0.613
History of stroke 11 (17.19%) 3 (10.00%) p = 0.347
Total cholesterol (mg/dL) 158.16 ± 39.82 159.6 ± 30.72 p = 0.22
LEAD 43 (67.19%) 17 (56.67%) p = 0.275
Claudicants 28 (43.75%) 15 (50.00%) p = 0.615
CLTI 15 (23.44%) 2 (6.67%) p = 0.046*
ABI right 0.83 ± 0.24 0.78 ± 0.29 p = 0.287
ABI left 0.81 ± 0.28 0.77 ± 0.23 p = 0.671
Right carotid artery stenosis
50–70 4 (6.25%) 2 (6.67%) p = 0.952
>70% 58 (90.63%) 27 (90.00%) p = 0.702
Light carotid artery stenosis
50–70 3 (4.79%) 1 (3.33%) p = 0.787
>70% 4 (6.25%) 2 (6.67%) p = 0.903
Area right carotid plaque (mm2) 21.22 ± 19.81 20.01 ± 17.04 p = 0.622
Average IMT- right (mm) 0.96 ± 0.41 0.88 ± 0.24 p = 0.159
Area left carotid plaque (mm2) 21.46 ± 18.73 21.47 ± 22.06 p = 0.948
Average IMT- left (mm) 0.93 ± 0.25 0.88 ± 0.29 p = 0.861
Table 2 
Independent variables Categories a 95% CI p
CLTI Diabetes 1.488 1.34–14.60 0.014
Higher HGS −0.888 0.846–0.990 0.027
